Expert consensus on clinical application of Lixuwang~® Xuesaitong Soft Capsules.
10.19540/j.cnki.cjcmm.20230630.501
- Author:
Min JIA
1
;
Xiao LIANG
1
;
Guo-Jing FU
1
;
Xiang-Lan JIN
2
;
Yan LU
1
;
Xing LIAO
3
;
Yun-Ling ZHANG
1
Author Information
1. Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
2. Dongfang Hospital,Beijing University of Chinese Medicine Beijing 100078, China.
3. Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences Beijing 100700, China.
- Publication Type:Journal Article
- Keywords:
Chinese patent medicine;
Xuesaitong Soft Capsules;
angina pectoris in coronary heart disease;
expert consensus;
ischemic stroke
- MeSH:
Humans;
Consensus;
Drugs, Chinese Herbal/therapeutic use*;
Medicine, Chinese Traditional;
Coronary Disease/drug therapy*;
Ischemic Stroke/drug therapy*;
Capsules
- From:
China Journal of Chinese Materia Medica
2023;48(20):5668-5674
- CountryChina
- Language:Chinese
-
Abstract:
Lixuwang~® Xuesaitong Soft Capsules(referred to as "Xuesaitong Soft Capsules") have the effects of promoting blood circulation, resolving blood stasis, and dredging meridians and collaterals. They are widely used in the prevention and treatment of cardiovascular and cerebrovascular diseases in clinical practice. Through years of clinical observation, they have shown significant efficacy in ischemic stroke, coronary heart disease, and other diseases, and have been recommended by multiple guidelines, consensus statements, and monographs. Based on the summary of clinical application experience by doctors and existing evidence-based research, following the Technical Specifications for Consensus Development of Chinese Patent Medicine by Clinical Experts issued by Standardization Office of the Chinese Association of Traditional Chinese Medicine, a nominal group method was used to reach 19 recommended opinions/consensus suggestions. This document proposes the timing of medication, syndrome differentiation for medication, therapeutic effects, dosage and administration, treatment duration, economic considerations, and safety considerations in the use of Xuesaitong Soft Capsules for the treatment of ischemic stroke and angina pectoris in coronary heart disease. It is intended for doctors in internal medicine, encephalopathy(neurology), cardiovascular medicine, geriatrics, emergency medicine, general practice, and traditional Chinese medicine departments of various medical institutions, as well as pharmacists in hospitals and pharmacies, as a medication reference when using Xuesaitong Soft Capsules. It is hoped that the widespread application of this consensus can improve the clinical efficacy of Xuesaitong Soft Capsules in the treatment of ischemic stroke and coronary heart disease, promote rational drug use, and reduce medication risks. This consensus has been reviewed and published by the China Association of Traditional Chinese Medicine, with the identification number GS/CACM 323-2023.
